Supplier News: Esteve CDMO, Axplora, Bora, Garonit Pharmaceuticals & More
The latest from CDMOs, CMOs, and suppliers featuring Garonit Pharmaceuticals, Axplora, Bora Pharmaceuticals, Esteve CDMO, Asahi Kasei, and Solvias USA.
Chemicals/Chemical API Manufacturing
* Ofichem Acquires Early-Phase Drug-Substance Site from Meribel Pharma Solutions
* Axplora Announces $7.8-M Facility Expansion
* Esteve CDMO Acquires Regis Technologies
Biologics Manufacturing
* Asahi-Kasei Expands Mfg for Virus Removal Filters
End to End (Drug Substance and Drug Product)
* Garonit Pharmaceuticals Investing $46.1 M in New Mfg Plant for Chlorhexidine Gluconate
Formulation Development/Drug Product Manufacturing
* Bora Pharmaceuticals To Expand Oral Solid Dosage, Packaging Capacity
General
* Solvias USA Names New President
Chemicals/Chemical API Manufacturing
Ofichem Acquires Drug Substance Site from Meribel Pharma Solutions
Ofichem, a Ter Apel, the Netherlands-based supplier of active pharmaceutical inredients (APIs), has acquired Meribel Pharma Solutions’ early-phase drug-substance site in Uppsala, Sweden. Meribel Pharma Solutions launched as a new CDMO of primarily of drug products following the acquisition of the CDMO, Synerlab Group, and seven European manufacturing facilities from the CDMO, Recipharm, last year (2024).
The Uppsala site, formerly part of Recipharm and known as OT Chemistry, has 20 employees and specializes in small-scale, early-phase development work. The expertise at the facility spans traditional small molecules and emerging modalities such as antibody-drug conjugates oligonucleotides and proteolysis-targeting chimeras (PROTACs) and expands Ofichem’s non-GMP capabilities in early-stage development.
Source: Ofichem
Axplora Announces $7.8-M Facility Expansion
Axplora, a CDMO of small-molecule active pharmaceuticals ingredients (APIs), intermediates, and antibody drug conjugates (ADCs), and a provider of industrial chromatography services, has announced a EUR 6.5-million ($7.8-million) investment at its site in Vizag, India, to expand production capacity.
This announcement follows the successful completion of routine inspections by the US Food and Drug Administration in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of the company’s PharmaZell Business Unit.
Source: Axplora
Esteve CDMO Acquires Regis Technologies
Esteve CDMO, part of Esteve, a Barcelona-based pharmaceutical company and CDMO, has acquired Regis Technologies, a Morton Grove, Illinois-based CDMO of active pharmaceutical ingredients (APIs) and related services, including process research & development, analytical & stability testing, cGMP API manufacturing, CMC support, and a provider of a variety of chromatography products.
Esteve CDMO (Esteve Química) is a global pure-play CDMO, specializing in small-molecule APIs and pharmaceutical intermediates, including specialized services, such as spray-drying and high-potency API manufacturing. The acquisition provides Esteve CDMO with a physical presence in the US.
Esteve has two main businesses: its CDMO business with production plants in Spain, Mexico, China, and now the US, and the pharmaceutical business, which provides specialized medicines through affiliates in Germany, Spain, France, Italy, Portugal, the UK, as well as a presence in the US.
Source: Esteve
Biologics Manufacturing
Asahi-Kasei Expands Mfg for Virus Removal Filters
Asahi Kasei Life Science, a division of the global manufacturer, Asahi Kasei, has announced plans to construct a new spinning plant for its Planova virus removal filters in Nobeoka City, Miyazaki, Japan. The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters. Construction is scheduled to begin in July 2026, with operations starting in January 2030.
Source: Asahi Kasei
End to End (Drug Substance and Drug Product)
Garonit Pharmaceuticals Investing $46.1 M in New Mfg Plant for Chlorhexidine Gluconate
Garonit Pharmaceuticals, a global manufacturer of antiseptic products and healthcare solutions, will establish a $46.1-million, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County, New York, for the production of chlorhexidine gluconate, an antiseptic product used in hospitals for surgical disinfection and infection prevention.
Garonit Pharmaceutical was founded in 1994 in Mumbai, India, and specializes in antiseptic ingredients and healthcare solutions for medical facilities worldwide. The company operates manufacturing sites in the US and India, with additional operations in the UK, Hong Kong, and Japan.
The new facility will serve as a chlorhexidine gluconate manufacturing operation and will manufacture antiseptic products, including both abbreviated new drug application and new drug application formulations. The products to be manufactured at this site are commonly used in hospital settings, particularly in surgical environments, with the initial product portfolio focusing on antiseptics designed to maintain sterility and support cleanliness during a wide range of medical procedures. The 200,000-square-foot facility will feature advanced production lines for liquid finished dosage forms and a laboratory equipped with advanced analytical equipment for quality testing and research. The facility will also house a fully equipped research and development center dedicated to the development of both active pharmaceutical ingredients and finished dosage forms.
Construction is scheduled to begin in the first quarter of 2026, with production operations anticipated to start in January 2027. The project will create an estimated 100 to 150 construction jobs during the build phase, and the 100 full-time pharmaceutical positions will include production, quality assurance, warehouse, R&D, administration and logistics, management, and sales roles. The facility will export products to existing customers across North America, Europe, Japan, Australia, and other global markets.
New York State is supporting the project with $3.8 million, including up to $3.5 million through the Excelsior Jobs Program and a $300,000 Mid-Hudson Regional Economic Development Council capital grant.
Source: New York Office of the Governor
Formulation Development/Drug Product Manufacturing
Bora Pharmaceuticals To Expand Oral Solid Dosage, Packaging Capacity
Bora Pharmaceuticals has announced plans to expand its oral solid dosage manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota. The expansion is an upgrade to the site, which Bora acquired as part of its $210-million acquisition of Upsher-Smith Laboratories. The site expands Bora’s US manufacturing footprint.
The first phase of Bora’s investment will add a Gerteis Macro-Pactor roller compactor at the site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed for partners with high-volume needs. The roller compactor will be installed and operational in the third quarter of 2025.
Source: Bora Pharmaceuticals
General
Solvias USA Names New President
Solvias, a provider of chemistry, manufacturing, and controls (CMC) analytical services, has appointed Jarlath Keating as President Solvias Group USA. Keating has nearly 30 years of experience in the bio/pharmaceutical and biotechnology sectors. His leadership spans senior executive roles at Phosphorex, Advanced Bioscience Laboratories, and BioReliance.
Source: Solvias
